CClinicalTrials.gg
RecruitingNCT07010341Updated Jul 15, 2025

Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence Imaging

An observational study in Thyroid Surgery, sponsored by Fujian Medical University. Recruiting at 2 sites in China. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Fujian Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
210
Sex
All
01

Study summary

This single-center, prospective, three-phase observational cohort quantifies the relationship between indocyanine green (ICG) fluorescence and early parathyroid function. Adult patients scheduled for unilateral thyroid lobectomy with autotransplantation of the ipsilateral inferior parathyroid gland are enrolled. After intravenous ICG 25 µg/kg, peak fluorescence of the superior parathyroid gland and the common carotid artery (CCA) is recorded at 60-120 seconds to calculate the ratio R = PTG/CCA. Serum parathyroid hormone (PTH) is measured 30 minutes post-operatively. A derivation cohort (\~120 patients) generates R-based thresholds for in-situ preservation versus autotransplantation, which are prospectively validated in an independent cohort (60 patients) together with decision-curve analysis of clinical net benefit.

Read the detailed description

Post-thyroidectomy hypocalcemia, reported in 5-30 % of cases, is largely attributable to inaccurate assessment of parathyroid perfusion. Conventional intra-operative judgment-based on gland color, capillary bleeding and pulsation-is subjective and non-quantitative. Near-infrared fluorescence imaging with indocyanine green (ICG) allows real-time visualization of tissue perfusion, yet no widely accepted quantitative threshold exists to guide in-situ preservation versus autotransplantation of parathyroid glands.

The PT-ICG study addresses this gap through:

Target population: Patients undergoing unilateral thyroid lobectomy with planned autotransplantation of the ipsilateral inferior parathyroid gland, isolating evaluation to the superior gland.

Pilot phase (n=30): Optimization confirmed an ICG dose of 25 µg/kg and a 60-120 s acquisition window, with the common carotid artery (CCA) providing a stable reference; well-perfused glands exhibited R values \~0.8-3.0.

Derivation phase (n≈120): The relationship between R and 30-min postoperative PTH is modeled; ROC analysis and the Youden index yield R_low and R_high thresholds, internally validated with bootstrap resampling.

Validation phase (n=60): Prospective application of thresholds documents surgeon decisions, postoperative PTH, and hypocalcemia incidence; predictive performance (AUC, sensitivity, specificity) and net clinical benefit (decision-curve analysis) of the R-based strategy are compared with standard clinical judgment.

Sample size and statistics: With an anticipated correlation r≈0.45, α=0.05 (two-sided) and 90 % power, ≥110 patients are required; allowing 10 % attrition, 120-130 will be enrolled.

Data management and safety: REDCap will support double data entry and monitoring; ICG-related adverse events will be recorded; the study adheres to GCP and the Declaration of Helsinki and has received ethics committee approval.

By establishing actionable ICG fluorescence thresholds and a decision algorithm, the study seeks to provide a quantitative tool for real-time intra-operative perfusion assessment, potentially reducing hypocalcemia and informing future multicenter trials.

full SAP available upon request / will be posted as separate document.

02

Conditions studied

  • Thyroid Surgery

Browse trials for

Keywords

  • Thyroid surgery
  • Indocyanine Green
  • Near-Infrared Fluorescence
  • Parathyroid Perfusion
  • Perfusion Threshold
  • Hypocalcemia
  • Perfusion Ratio
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive adult patients undergoing unilateral thyroid lobectomy with planned autotransplantation of the ipsilateral inferior parathyroid gland at a single tertiary endocrine-surgery center; recruitment limited to cases in which the superior parathyroid gland can be preserved in situ and evaluated intra-operatively with indocyanine-green fluorescence quantification.

Inclusion criteria

  • Scheduled for unilateral thyroid lobectomy plus central (VI-level) lymph-node dissection.
  • Intra-operative findings consistent with:
  • Complete identification and in-situ preservation of the ipsilateral superior parathyroid gland;
  • Complete identification and autotransplantation of the ipsilateral inferior parathyroid gland.
  • Serum 25-hydroxy-vitamin D ≥ 30 ng/mL at baseline; patients below this level may be enrolled after standardized vitamin-D and calcium supplementation with re-test confirming ≥ 30 ng/mL.
  • Surgery and all postoperative follow-up performed at the study center.
  • Able and willing to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Prior surgery on the thyroid or parathyroid glands.
  • Severe hepatic or renal impairment, or other serious metabolic bone disease.
  • Pregnancy or lactation.
  • Known hypersensitivity to indocyanine green or iodine-containing compounds.
  • Inability or unwillingness to comply with postoperative visits and blood testing.
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
210 participants (estimated)
Patient registry
No

Groups and cohorts

  • Derivation_Cohort

    The model-development cohort consisted of 500 consecutive patients drawn from the Thyroid Surgery Department database of Fujian Medical University Union Hospital (Fuzhou, China)

    Diagnostic Test: ntra-operative Indocyanine Green (ICG) Fluorescence Quantification

  • Validation_Cohort

    The external validation cohort comprised 300 patients

    Diagnostic Test: ntra-operative Indocyanine Green (ICG) Fluorescence Quantification

Interventions

  • Diagnostic testntra-operative Indocyanine Green (ICG) Fluorescence Quantification

    After a single intravenous bolus of indocyanine green (25 µg/kg), a near-infrared sensor records raw fluorescence intensity from the superior parathyroid gland and the ipsilateral common carotid artery at 60-120 seconds. No images are stored; only peak intensity values are logged to calculate the perfusion ratio R = PTG / CCA. The measurement is observational, adds ≤2 minutes to operative time, and involves no therapeutic intent.

05

What researchers measure

Primary outcomes

  1. Parathyroid Gland Fluorescence Intensity

    Peak fluorescence intensity of the ipsilateral superior parathyroid gland, captured 60 - 120 seconds after a single intravenous bolus of indocyanine green (25 µg/kg).

    Time frame: Intra-operative (60 - 120 s post-ICG)

  2. Common Carotid Artery (CCA) Fluorescence Intensity

    Peak fluorescence intensity of the ipsilateral common carotid artery recorded in the same 60 - 120 second window; serves as the reference signal for perfusion ratio calculations.

    Time frame: Intra-operative (60 - 120 s post-ICG)

  3. Parathyroid Hormone (PTH) at 30 Minutes post-surgery

    PTH concentration (pg/mL) measured by chemiluminescent assay 30 minutes after skin closure, reflecting immediate functional status of the preserved superior parathyroid gland.

    Time frame: 30 minutes after surgery

Secondary outcomes

  1. Administered ICG Dose

    Total dose of indocyanine green (µg/kg) delivered during the procedure.

    Time frame: Intra-operative (time of injection)

  2. PTH at 6 Hours

    PTH concentration measured 6 hours after surgery.

    Time frame: 6 hours post-surgery

  3. PTH at 2 Weeks

    PTH concentration measured 14 ± 2 days after surgery.

    Time frame: 2 weeks post-surgery

06

Study locations

1 of 2 sites recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    • Bo Wang, MD · Contact · wangbo@fjmu.edu.cn · +13959123550
    • Bo Wang MD, Principal Investigator · Principal investigator
    Not yet recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07010341
Lead sponsor
Fujian Medical University
Responsible party
Bo Wang,MD (Director, Head of Thyroid Surgery, Principal Investigator, Clinical Professor, Fujian Medical University) — Principal investigator
First posted
Jun 8, 2025
Start date
May 1, 2025
Primary completion
Nov 30, 2025 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Jul 15, 2025

Study contacts

Bo Wang, MD
Contact
wangbo@fjmu.edu.cn
+13959123550

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion